Table 2.
The characteristics of CMR
| Normal (n = 25) | hs-TnI (+, n = 8) | hs-TnI (−, n = 17) | P | |
|---|---|---|---|---|
| LVEDV (mL) | 107.6 (98.7–128.3) | 116.5 (99.7–127.1) | 113.8 (100.5–129.8) | 0.96 |
| LVESV (mL) | 43.2 ± 15.5 | 58.7 ± 17a | 51.2 ± 9.6 | 0.020 |
| SV (mL) | 67.5 (65.2–79.8) | 58.8 (53.5–67.6)a | 61.3 (55.4–72.3)b | 0.030 |
| HR (/min) | 65 (63–71) | 73 (63.5–81) | 72 (69.5–73.5)b | 0.030 |
| CO (L/min) | 4.8 (4.4–5.5) | 4.66 (4.3–6) | 4.3 (4–5.3) | 0.26 |
| LVEF (%) | 64.6 ± 4.6 | 52.4 ± 2.8a | 55.1 ± 6.1b | <0.001 |
| MyoMass (g) | 87.1 (74.6–114.9) | 91.6 (79.9–103.7) | 80.2 (74.3–104.2) | 0.77 |
| iLVEDV (mL/m2) | 69.8 (64.1–70.8) | 66.9 (60.9–74.8) | 66.2 (61–72.4) | 0.72 |
| iLVESV (mL/m2) | 25.4 ± 6.3 | 30.3 ± 5.2a | 29.9 ± 5.2b | 0.020 |
| iSV (mL/m2) | 42.9 (40.3–51.4) | 35.9 (33.3–46.1)a | 36.8 (34.4–38.3)b | <0.001 |
| CI (L/min/m2) | 2.9 (2.7–3.2) | 2.7 (2.4–3.5) | 2.6 (2.4–2.7)b | 0.002 |
| pGLS (%) | −15.7 (−18.3– −12.7) | −12.3 (−13.3– −11.5)a | −13.1 (−14.2–−9.8)b | 0.004 |
| Native T1 | 1065 ± 57 | 1169.8 ± 12.9a | 1113.2 ± 31.2b,c | <0.001 |
| ECV | 26 (24–27.5) | 32 (31–33)a | 29 (27–30)b,c | <0.001 |
| T2 mapping | 42 (41–45.2) | 51 (47.9–52.8)a | 48 (47–49.4)b | <0.001 |
Numbers are given as median (interquartile ranges) or mean ± standard deviation or as absolute frequency with percentages in parentheses.
CI, cardiac index; CO, cardiac output; HR, heart rate; i, index; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricle ejection fraction; LVESV, left ventricular end-systolic volume; MyoMass, Myocardial Mass; Normal, control group; pGLS, peak global longitudinal strain; SV, stroke volume.
a
P value <0.05 for comparing COVID-19 patients with positive hs-TnI and controls.
b
P value <0.05 for comparing COVID-19 patients with negative hs-TnI and controls.
c
P value <0.05 for comparing COVID-19 patients with positive and negative hs-TnI.